

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## **CHANGE IN INDEPENDENT NON-EXECUTIVE DIRECTORS AND COMPOSITION OF THE STRATEGIC COMMITTEE**

Reference is made to the announcement dated 9 December 2022 (the “**Previous Announcement**”) and circular dated 7 June 2023 (the “**Circular**”) of Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) in relation to, among other things, the proposed appointment of Dr. Meng Anming (“**Dr. Meng**”) as an independent non-executive director (the “**Director**”) of the Company.

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that resolution number 10 regarding the appointment of Dr. Meng as an independent non-executive Director was approved at the 2022 annual general meeting of the Company (“**AGM**”) held on 30 June 2023. The appointment of Dr. Meng as an independent non-executive Director has become effective on the date of the AGM, being 30 June 2023. Poll results of the AGM are set out in the poll results announcement of the Company dated 30 June 2023.

The biographical details and other relevant information regarding Dr. Meng are set out in the Previous Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Dr. Meng in relation to his appointment as an independent non-executive Director for a term commencing from the date of approval of his appointment at the AGM, being 30 June 2023, and expiring on the conclusion of the third session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, the director's fee payable to Dr. Meng will be RMB300,000 per annum, which was determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Dr. Meng has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Dr. Meng has confirmed that he has met the independence criteria set out in Rule 3.13 of the Hong Kong Listing Rules.

Save as disclosed above, there are no other matters concerning Dr. Meng's appointment as an independent non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

#### **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

As disclosed in the Previous Announcement, Dr. Chen Lieping (“**Dr. Chen**”) has resigned as an independent non-executive Director and a member of the Strategic Committee. Dr. Chen's resignation has become effective upon the date of appointment of Dr. Meng as an independent non-executive Director, being 30 June 2023. Dr. Chen has confirmed that he has no disagreement with the Board, and there are no other matters that should be brought to the attention of the Shareholders in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Chen for his contributions to the Company during his tenure of office.

## CHANGE IN COMPOSITION OF THE STRATEGIC COMMITTEE

The Board is pleased to announce that, following the resolution regarding the appointment of Dr. Meng as an independent non-executive Director being passed at the AGM and the resignation of Dr. Chen as an independent non-executive Director, with effect from 30 June 2023, Dr. Meng will be appointed as a member of the Strategic Committee and Dr. Chen will cease to be a member of the Strategic Committee.

Following the above change, the Strategic Committee will comprise three independent non-executive Directors, namely Dr. Roy Steven Herbst, Mr. Zhang Chun, and Dr. Meng Anming, and two executive Directors, namely Mr. Xiong Jun (chairman of the Strategic Committee) and Dr. Li Ning.

The Board would like to take this opportunity to extend a warm welcome to Dr. Meng for joining the Board.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 30 June 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.*

\* *For identification purpose only*